Novartis, Serono In MS Race To Market First Oral Therapy
The much-touted multiple sclerosis drug from Biogen Idec Inc., which pumped investors' hopes and then bombed, continues to grab headlines, albeit smaller ones. The drug was pulled from the market in February after it was linked to patient deaths from progressive multifocal leukoencephalopathy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter